NEW YORK – Daiichi Sankyo said on Wednesday that it has dosed the first triple-negative breast cancer patient in a Phase I study evaluating the investigational agent DS-1062.
The TROP2-directed DXd antibody-drug conjugate previously demonstrated encouraging efficacy in non-small cell lung cancer patients. Based on that, Daiichi Sankyo expanded the study to include TNBC patients, who lack treatment options since their tumors lack expression of HER2, estrogen, and progesterone receptors. However, up to 80 percent of TNBC patients have high TROP2 expression.